 | Up a level |
Journal Article
Nogova, Lucia, Mattonet, Christian, Scheffler, Matthias 
ORCID: 0000-0002-9031-1368, Taubert, Max ORCID: 0000-0001-8925-7782, Gardizi, Masyar, Sos, Martin L., Michels, Sebastian, Fischer, Rieke N., Limburg, Meike, Abdulla, Diana S. Y., Persigehl, Thorsten, Kobe, Carsten, Merkelbach-Bruse, Sabine, Franklin, Jeremy, Backes, Heiko, Schnell, Roland, Behringer, Dirk, Kaminsky, Britta, Eichstaedt, Martina, Stelzer, Christoph, Kinzig, Martina, Soergel, Fritz, Tian, Yingying, Junge, Lisa, Suleiman, Ahmed A., Frechen, Sebastian, Rokitta, Dennis, Ouyang, Dongsheng, Fuhr, Uwe, Buettner, Reinhard and Wolf, Juergen
(2020).
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Cancer Med., 9 (14).
S. 4991 - 5008.
HOBOKEN:
WILEY.
ISSN 2045-7634
Suleiman, Ahmed A., Frechen, Sebastian, Scheffler, Matthias, Zander, Thomas, Wolf, Juergen, Nogova, Lucia and Fuhr, Uwe (2014). A MODELING FRAMEWORK FOR THE ASSESSMENT OF [(18)F]-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN PREDICTING OVERALL SURVIVAL IN NON-SMALL CELL LUNG CANCER. Drug Metab. Rev., 45. S. 229 - 230. LONDON: INFORMA HEALTHCARE. ISSN 1097-9883